We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Sep 5, 2018

Society of Hematologic Oncology Sixth Annual Meeting

19 / Durability of Response in Patients With Refractory Large B Cell Lymphoma Treated With Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1

;

Locke;

Frederick L.;

frederick.locke@moffitt.org;

Presenter;

Ghobadi;

Armin;

arminghobadi@wustl.edu;

Jacobson;

Caron A.;

caron_jacobson@dfci.harvard.edu;

Jacobsen;

Eric;

eric_jacobsen@dfci.harvard.edu;

Miklos;

David B.;

dmiklos@stanford.edu;

Lekakis;

Lazaros J.;

llekakis@med.miami.edu;

Braunschweig;

Ira;

IBRAUNSC@montefiore.org;

Oluwole;

Olalekan O.;

olalekan.oluwole@Vanderbilt.Edu;

Lin;

Yi;

lin.yi@mayo.edu;

Siddiqi;

Tanya;

tsiddiqi@coh.org;

Deol;

Abhinav;

deola@karmanos.org;

Reagan;

Patrick M.;

patrick_reagan@urmc.rochester.edu;

Farooq;

Umar;

umar-farooq@uiowa.edu;

Bot;

Adrian;

abot@kitepharma.com;

Jiang;

Yizhou;

jjiang@kitepharma.com;

Rossi;

John M.;

jrossi@kitepharma.com;

Xue;

Allen;

axue@kitepharma.com;

Go;

William Y.;

Wgo@kitepharma.com;

Neelapu;

Sattva S.;

sneelapu@mdanderson.org

car t cell therapy

large b cell lymphoma

Abstract

9

Views

9

Views

Abstract

Fullscreen

thumbnail

Keywords

car t cell therapy

large b cell lymphoma

Abstract

CONTEXT: Axicabtagene ciloleucel (axi-cel), an anti-CD19 CAR T cell therapy, demonstrated significant clinical benefit and a manageable safety profile for patients with refractory large B cell lymphoma in ZUMA-1 (Neelapu & Locke, et al. NEJM. 2017). These results led to its approval by the US FDA for the treatment of adult patients with relapsed or refractory large B cell lymphoma after ≥ 2 prior lines of therapy. OBJECTIVE: We examined responses over time in Phase 2 of ZUMA-1. DESIGN: Patients with refractory large B cell lymphoma received 2 × 106 CAR T cells/kg after low-dose conditioning (Neelapu & Locke, et al. NEJM. 2017). Best objective response rates (BOR) were analyzed locally by investigators (local) and centrally by independent review committee (IRC; Cheson, et al. J Clin Oncol. 2007); concordance was measured as the percentage of patients whose IRC matched local. RESULTS: As of 8/11/17, median follow-up was 15.1 months for the 101 patients treated with axi-cel. While the BOR of 82% at primary analysis (median follow-up 8.7 months) by local remained consistent (83%) at long-term follow-up (median of 15.1 months), complete response (CR) rates increased from 54% to 58%. Of 34 patients with a partial response (PR) at 1 month, 11 (32%) converted to CR by the long-term follow-up. High concordance (77% – 79%) was observed for objective response rates (ORR [CR + PR]) between local and IRC at all times assessed. Landmark analysis of progression-free survival (PFS) by response status (per local) revealed that most of the 60 patients with disease control (stable disease or better) at 3 months had prolonged disease control with a 73% 12-month PFS rate. Of the 42 patients with CR and 9 with PR at 3 months, the 12-month PFS rates were 79% and 78%, respectively. CONCLUSIONS: Axi-cel induces high response rates in patients with refractory large B cell lymphoma. CR rates increased through the long-term follow-up, suggesting that responses deepen over time and that patients with PR can achieve CR as late as a year post-infusion. ORR at 3 months may be prognostic for prolonged PFS. FUNDING SOURCE: Kite, a Gilead Company

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.